A methodology change could lead to 20 deletions in Sep. Estimated one-way turnover at the rebalance is 9.5% resulting in a round-trip trade of HK$1.3bn (US$162m). Passives need to sell 0.05-1x ADV.
What is covered in the Full Insight:
Introduction to Hang Seng Biotech Index Rebalance
Details of Methodology Change
Expected Changes at the September Review
Potential Inclusions and Deletions
Estimated Passive Flow and Basket Performance
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.